CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79.75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Germany's Stratec to sell unit Diatron MI; lifts 2026 adjusted operating margin

By Reuters News


Overview

  • Germany diagnostics systems provider to sell loss-making Diatron MI business for €10 mln plus earn-outs

  • Company to book €44.1 mln impairment in Q3 and €4-9 mln deconsolidation loss in Q4

  • Nine-month 2026 prelim sales €164.9 mln, prelim adjusted EBIT margin 8.3%, both including divested unit


Outlook

  • STRATEC expects 2026 sales to be stable to slightly higher than €223.5 mln on constant-currency basis

  • Company forecasts 2026 adjusted EBIT margin of 13.0%-15.0% after divestment, up from prior 10.0%

  • STRATEC says previous medium-term targets are withdrawn and will be updated with 2026 annual report


Result Drivers

  • DIVESTMENT OF LOSS-MAKING UNIT - Co said sale of Diatron MI, which generated negative EBIT, will remove loss-making operations from group results


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

9M Prelim Revenue

EUR 164.90 mln

9M Prelim Adjusted EBIT Margin

8.30%


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for Stratec Se is €23.00, about 2.2% above its October 30 closing price of €22.50

  • The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 10 three months ago


Reuters Recommended Reads

  • Oct 29 - Draegerwerk 9M net sales rise, EBIT jumps on one-off gains

  • Oct 30 - Germany's Gerresheimer prelim Q3 revenue rises on strong demand for drug delivery devices

  • Oct 29 - Resmed Q1 revenue beats estimates on sleep devices, mask demand


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.